S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
TOVX · Theriva Biologics, Inc.
NYSE MKT LLC - BOATS Real Time Price • USD
$0.20
-0.01
(-5.14%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$0.20
$0.20
$0.21
52-WEEK RANGE
$0.20
$0.16
$0.85
What's happening
- TOVX is down 5.14% today, trading at $0.20. — Live quote
- Volume today (414) is well below its 3-month average of 1,125,640. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.07 actual vs. $-0.05 estimated (-37.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 5
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (8 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
TOVX
-1.14%
vs S&P 500
-13.92%
1-YEAR RETURN
TOVX
-37.54%
vs S&P 500
-52.10%
6-MONTH RETURN
TOVX
-17.56%
3-MONTH RETURN
TOVX
-9.57%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.07
Est. $-0.05
MISS -37.3%
2026-04-26 (Q1 2026)
$-0.05
Est. $-0.05
BEAT +2.0%
2026-01-26 (Q4 2025)
$-0.29
Est. $-0.44
BEAT +34.6%
2025-10-26 (Q3 2025)
$-0.45
Est. $-0.77
BEAT +41.6%
Valuation Measures & Ratios
Enterprise Value4$21.0K
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)32.35
Price / Book70.94
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin-681.33%
Operating Margin-709.00%
Return on Equity (ROE8)-93.49%
Return on Assets (ROA9)-32.69%
Avg Volume (3M)1,125,640
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short1,712,533
Change from Prior Settlement+7.74%
% of Float—
Days to Cover (Short Ratio)3.90
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 10-Q, filed 2026-08-11; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -681.3%. Finnhub fundamentals ↗
- Trailing 52-week price return is -37.5%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on TOVX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $300.0K | — | — | — | — | — | — |
| Operating income | -$3.3M | -$2.1M | -$4.4M | -$13.1M | -$4.4M | -$7.9M | -$8.5M | -$5.4M |
| Net income | — | — | — | — | — | — | — | — |
| EPS (diluted) | $-0.07 | $-0.05 | $-0.45 | $-1.93 | $-1.55 | $-6.81 | $-10.72 | $-7.53 |
| EPS (basic) | $-0.07 | $-0.05 | $-0.45 | $-1.93 | $-1.55 | $-6.81 | $-10.72 | $-7.53 |
| Operating margin | — | -$709 | — | — | — | — | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $34.9M | $38.2M | $38.2M | $30.8M | $35.8M | $32.2M | $35.4M | $40.1M |
| Total liabilities | $22.7M | $22.8M | $22.9M | $24.1M | $25.2M | $16.7M | $16.3M | $15.5M |
| Stockholders' equity | — | — | — | — | — | — | — | — |
| Total current assets | $13.7M | $16.8M | $17.5M | $9.9M | $14.7M | $12.5M | $16.3M | $19.5M |
| Total current liabilities | $12.1M | $10.3M | $10.0M | $11.0M | $12.4M | $8.1M | $7.6M | $7.3M |
| Cash & equivalents | $11.3M | $14.4M | $13.1M | $7.5M | $12.1M | $10.0M | $11.6M | $16.4M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Other current assets | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $173.0K | $194.0K | $222.0K | $249.0K | $258.0K | $253.0K | $270.0K | $314.0K |
| Goodwill | — | — | — | — | — | — | $0 | — |
| Intangible assets | $19.1M | $19.2M | $19.6M | $19.6M | $19.6M | $18.1M | $17.4M | $18.7M |
| Accounts payable | $984.0K | $608.0K | $1.0M | $795.0K | $607.0K | $437.0K | $859.0K | $756.0K |
| Accrued liabilities | $6.4M | $6.2M | $6.3M | $7.7M | $9.0M | $3.8M | $3.4M | $3.8M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | $1.7M | — | — | — | $92.0K | — |
| Common stock & paid-in capital | $45.0K | $45.0K | $34.0K | $9.0K | $8.0K | $3.0K | $3.0K | $3.0K |
| Retained earnings | -$364.0M | -$360.8M | -$358.7M | -$356.7M | -$352.4M | -$339.3M | -$335.0M | -$330.5M |
| Accumulated other comprehensive income (loss) | $247.0K | $377.0K | $755.0K | $763.0K | $793.0K | -$524.0K | -$1.2M | $112.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.1M | -$2.5M | -$2.9M | -$4.3M | -$4.7M | -$4.8M | -$4.7M | -$3.9M |
| Investing cash flow | -$3.0K | — | $0 | -$19.0K | -$16.0K | — | $0 | $0 |
| Financing cash flow | -$14.0K | $3.9M | $8.5M | -$148.0K | $6.8M | $3.1M | $7.0K | $3.7M |
| Free cash flow | -$3.1M | — | -$2.9M | -$4.3M | -$4.7M | — | -$4.7M | -$3.9M |
| Capital expenditures | $3.0K | — | $0 | $19.0K | $16.0K | — | $0 | $0 |
| Depreciation & amortization | $24.0K | $24.0K | $27.0K | $28.0K | $27.0K | $26.0K | $27.0K | $33.0K |
| Share-based compensation | $135.0K | $135.0K | $153.0K | $228.0K | $173.0K | $100.0K | $162.0K | $177.0K |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in accounts payable | $389.0K | -$397.0K | $209.0K | $161.0K | $139.0K | -$440.0K | $144.0K | -$200.0K |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt issued | — | — | $15.0K | $34.0K | $57.0K | $1.4M | — | — |
| Debt repaid | — | — | — | — | — | $56.0K | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$24.1M | -$26.3M | -$21.4M | -$21.6M | -$14.3M |
| Net income | — | — | -$18.3M | -$19.7M | -$14.3M |
| EPS (diluted) | $-2.08 | $-19.03 | $-28.48 | $-1.31 | $-1.90 |
| EPS (basic) | $-2.08 | $-19.03 | $-28.48 | $-1.31 | $-1.90 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Sep '22 |
|---|---|---|---|---|---|
| Total assets | $38.2M | $35.4M | $55.2M | $71.9M | $77.1M |
| Total liabilities | $22.9M | $16.3M | $15.5M | $17.3M | $18.0M |
| Stockholders' equity | — | — | — | — | $56.4M |
| Total current assets | $17.5M | $16.3M | $27.4M | $45.5M | $52.7M |
| Total current liabilities | $10.0M | $7.6M | $6.7M | $7.1M | $12.3M |
| Cash & equivalents | $13.1M | $11.6M | $23.2M | $41.8M | $50.5M |
| Accounts receivable | — | — | — | — | — |
| Other current assets | — | — | — | — | — |
| Property, plant & equipment | $222.0K | $270.0K | $422.0K | $345.0K | $262.0K |
| Goodwill | — | $0 | $5.7M | $5.5M | $5.2M |
| Intangible assets | $19.6M | $17.4M | $19.8M | $19.1M | $17.5M |
| Accounts payable | $1.0M | $859.0K | $770.0K | $915.0K | $770.0K |
| Accrued liabilities | $6.3M | $3.4M | $3.0M | $1.5M | $1.4M |
| Deferred revenue (current) | — | — | $906.0K | — | — |
| Short-term debt | — | — | $63.0K | $57.0K | — |
| Long-term debt | $1.7M | $92.0K | $162.0K | $221.0K | — |
| Common stock & paid-in capital | $34.0K | $3.0K | $1.0K | $16.0K | $16.0K |
| Retained earnings | -$358.7M | -$335.0M | -$309.3M | -$291.0M | -$284.5M |
| Accumulated other comprehensive income (loss) | $755.0K | -$1.2M | $32.0K | -$679.0K | -$2.7M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$16.7M | -$16.9M | -$19.0M | -$19.1M | -$12.9M |
| Investing cash flow | -$35.0K | -$1.0K | -$202.0K | -$4.4M | -$14.0K |
| Financing cash flow | $18.2M | $5.5M | $625.0K | -$1.9M | $74.0M |
| Free cash flow | -$16.7M | -$16.9M | -$19.2M | -$19.2M | -$12.9M |
| Capital expenditures | $35.0K | $1.0K | $202.0K | $116.0K | $14.0K |
| Depreciation & amortization | $108.0K | $137.0K | $135.0K | $85.0K | $87.0K |
| Share-based compensation | $654.0K | $671.0K | $552.0K | $475.0K | $416.0K |
| Deferred income taxes | — | — | -$1.6M | -$1.4M | — |
| Change in accounts receivable | — | — | — | — | — |
| Change in accounts payable | $69.0K | $123.0K | -$157.0K | -$385.0K | -$363.0K |
| Purchases of investments | — | — | — | — | — |
| Share repurchases | — | — | — | — | — |
| Debt issued | $1.5M | — | — | — | — |
| Debt repaid | — | $67.0K | $75.0K | $1.4M | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding TOVX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2022-12-29 to 2023-06-07
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| SHALLCROSS STEVEN A | CEO and CFO | Open market purchase | 2023-06-07 | 14,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:34 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-11 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-08-04 | 8-K | 2026-08-03 | View on SEC.gov → |
| 2026-07-07 | 8-K | 2026-07-07 | View on SEC.gov → |
| 2026-06-11 | 8-K | 2026-06-11 | View on SEC.gov → |
| 2026-06-05 | 8-K | 2026-06-05 | View on SEC.gov → |
| 2026-05-05 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-05 | 8-K | 2026-05-05 | View on SEC.gov → |
| 2026-04-17 | 8-K | 2026-04-17 | View on SEC.gov → |
| 2026-04-09 | 8-K | 2026-04-09 | View on SEC.gov → |
| 2026-03-23 | 8-K | 2026-03-23 | View on SEC.gov → |
Recent news
Headlines about TOVX (Theriva Biologics, Inc.). Links open the publisher — we don’t host full articles.
-
Theriva Biologics Proposes 500 Million Share Increase and Warrant Ratification for November 18 Meeting
Kalkine Media · 2026-10-20 -
Stockholders face another vote on $0.54 warrants at Theriva Biologics (TOVX).
Stock Titan · 2026-10-20 -
Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine
Yahoo Finance · 2026-09-30 -
Theriva Biologics GAAP EPS of -$0.07 misses by $0.01
Seeking Alpha · 2026-08-11 -
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results
Yahoo Finance · 2026-08-11 -
Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Yahoo Finance · 2026-08-06 -
Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Yahoo Finance · 2026-07-07 -
Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research
Yahoo Finance · 2026-06-11
No headlines in this category right now — try “All”.